Gene expression and silencing for improved islet transplantation

Area of Science:

• Regenerative Medicine
• Gene Therapy
• Endocrinology

Background:

• Islet transplantation shows promise for type 1 diabetes treatment.
• Successful transplantation requires rapid islet revascularization and prevention of apoptosis.

Purpose of the Study:

• To enhance islet transplantation outcomes by co-expressing growth factors and anti-apoptotic genes.
• To investigate the efficacy of bipartite Adenovirus (Adv) vectors in improving islet survival and function.

Main Methods:

• Human islets were transduced with bipartite Adv vectors expressing human vascular endothelial growth factor (hVEGF) or human hepatocyte growth factor (hHGF) along with human interleukin-1 receptor antagonist (hIL-1Ra).
• Adv vectors also expressed caspase-3 short hairpin RNA (shRNA) to target pro-apoptotic genes.
• Transduced islets were transplanted into diabetic NOD-SCID mice, and outcomes were assessed by measuring blood glucose, serum insulin, c-peptide, and immunohistochemical staining.

Main Results:

• Co-expression of hVEGF/hHGF and hIL-1Ra or caspase-3 shRNA significantly reduced cytokine-induced apoptosis in islets.
• Transplanted islets demonstrated dose- and time-dependent gene expression.
• Transduction improved islet survival, leading to reduced blood glucose and increased insulin and c-peptide levels in recipient mice.

Conclusions:

• Bipartite Adv vectors efficiently co-express therapeutic genes, decreasing islet apoptosis.
• This gene therapy approach significantly improves the success of islet transplantation for type 1 diabetes.